SLC1A5-overexpressing NK cells + SLC1A5-targeting bispecific antibody

SLC1A5-overexpressing NK cells + SLC1A5-targeting bispecific antibody is a conceptual combination immunotherapy in which natural killer (NK) cells are genetically engineered to overexpress the neutral amino acid transporter SLC1A5 (also known as ASCT2) and are administered together with a bispecific antibody designed to bind SLC1A5 on tumor cells and an activating receptor such as CD16 on NK cells. The rationale is to enhance NK cell metabolic fitness and persistence via increased glutamine transport through SLC1A5 while simultaneously redirecting and tethering these NK cells to SLC1A5-expressing tumor cells through the bispecific antibody, thereby promoting targeted antibody-dependent cellular cytotoxicity. This approach is aligned with emerging strategies that modulate SLC1A5/SLC7A5 pathways to strengthen anti‑tumor immunity and with the broader class of NK cell engager bispecific antibodies in oncology, but there is no specific clinical candidate publicly reported under this exact name.